These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34463540)

  • 1. Aberrant mTOR/autophagy/Nurr1 signaling is critical for TSC-associated tumor development.
    Wang Y; Li C; Zhang Y; Zha X; Zhang H; Hu Z; Wu C
    Biochem Cell Biol; 2021 Oct; 99(5):570-577. PubMed ID: 34463540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.
    Li C; Chen H; Lan Z; He S; Chen R; Wang F; Liu Z; Li K; Cheng L; Liu Y; Sun K; Wan X; Chen X; Peng H; Li L; Zhang Y; Jing Y; Huang M; Wang Y; Wang Y; Jiang J; Zha X; Chen L; Zhang H
    Cell Death Differ; 2019 Oct; 26(10):2015-2028. PubMed ID: 30760873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
    Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
    J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
    Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
    Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
    Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
    Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
    Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
    J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
    Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
    J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
    Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
    Jones AT; Narov K; Yang J; Sampson JR; Shen MH
    Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets.
    Conte E; Boccanegra B; Dinoi G; Pusch M; De Luca A; Liantonio A; Imbrici P
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR/miR-142-3p/PRAS40 signaling cascade is critical for tuberous sclerosis complex-associated renal cystogenesis.
    Zhao S; Hao S; Zhou J; Chen X; Zhang T; Qi Z; Zhang T; Jalal S; Zhai C; Yin L; Bo Y; Teng H; Wang Y; Gao D; Zhang H; Huang L
    Cell Mol Biol Lett; 2024 Sep; 29(1):125. PubMed ID: 39333852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of TSC1 and TSC2 proteins in neuronal axons.
    Karalis V; Wood D; Teaney NA; Sahin M
    Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
    Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
    PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J; Wu S; Wu CL; Manning BD
    Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
    Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
    Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.